Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of atezolizumab plus bevacizumab or lenvatinib as first-line systemic therapy in patients with intermediate-stage hepatocellular carcinoma

Next Previous
Trial Profile

Study of atezolizumab plus bevacizumab or lenvatinib as first-line systemic therapy in patients with intermediate-stage hepatocellular carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Lenvatinib
  • Indications Liver cancer
  • Focus Therapeutic Use

Most Recent Events

  • 01 Jan 2024 Results comparing the outcomes of patients with intermediate stage hepatocellular carcinoma who received atezolizumab plus bevacizumab or lenvatinib as first-line systemic therapy. published in the Liver International
  • 29 Dec 2023 New trial record
  • 14 Nov 2023 Results presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top